- Home
- ANAB vs ETD Comparison
ANAB vs ETD Comparison
Compare ANAB & ETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ETD
- Stock Information
- Founded
- ANAB 2005
- ETD 1932
- Country
- ANAB United States
- ETD United States
- Employees
- ANAB N/A
- ETD N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ETD Home Furnishings
- Sector
- ANAB Health Care
- ETD Consumer Discretionary
- Exchange
- ANAB Nasdaq
- ETD Nasdaq
- Market Cap
- ANAB 621.1M
- ETD 692.5M
- IPO Year
- ANAB 2017
- ETD 1993
- Fundamental
- Price
- ANAB $26.94
- ETD $29.85
- Analyst Decision
- ANAB Buy
- ETD Hold
- Analyst Count
- ANAB 10
- ETD 2
- Target Price
- ANAB $49.00
- ETD $30.00
- AVG Volume (30 Days)
- ANAB 526.3K
- ETD 205.9K
- Earning Date
- ANAB 08-08-2025
- ETD 07-30-2025
- Dividend Yield
- ANAB N/A
- ETD 6.56%
- EPS Growth
- ANAB N/A
- ETD N/A
- EPS
- ANAB N/A
- ETD 2.25
- Revenue
- ANAB $111,872,000.00
- ETD $622,924,000.00
- Revenue This Year
- ANAB N/A
- ETD N/A
- Revenue Next Year
- ANAB $24.39
- ETD $0.96
- P/E Ratio
- ANAB N/A
- ETD $13.27
- Revenue Growth
- ANAB 387.20
- ETD N/A
- 52 Week Low
- ANAB $12.21
- ETD $24.55
- 52 Week High
- ANAB $41.31
- ETD $35.62
- Technical
- Relative Strength Index (RSI)
- ANAB 66.30
- ETD 58.79
- Support Level
- ANAB $25.48
- ETD $28.86
- Resistance Level
- ANAB $28.50
- ETD $30.33
- Average True Range (ATR)
- ANAB 1.26
- ETD 0.62
- MACD
- ANAB 0.02
- ETD -0.04
- Stochastic Oscillator
- ANAB 70.23
- ETD 58.78
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ETD Ethan Allen Interiors Inc.
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.